Meltdown, recovery and outlook

Published 07-APR-2017 10:37 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

It was a tale of two sessions in the US following the previous day’s meltdown which mainly came off the back of unexpected commentary from the Fed regarding unwinding the balance sheet.

As anticipated, there was early selling last night which dragged the Dow lower, but a mid-session kick saw the index hit a high of 20,746 points, before giving up most of those gains to finish at 20,662 points up less than 0.1% on the previous day’s close.

The NASDAQ performed a little better, gaining 0.2% to close at 5878 points.

All eyes now turn to President Trump’s meeting with Xi Jinping, and from a macro data perspective the non-farm payroll numbers which will be released on Friday.

Concerns regarding the likelihood of uncertainty rubbing off on other global markets heightened after US markets closed the previous day with the Nikkei 225 benchmark index falling 264 points or 1.4%.

Japan was the next main market to trade after US markets closed, and this negative sentiment suggested European markets may have been in for a tough night.

This looked to be very much on the cards as the FTSE 100 slumped from the previous day’s close of 7331 points to hit an early-morning low of 7258 points. However, it recovered some of that lost ground throughout the day to close at 7303 points, representing a decline of 0.4%.

Mainland European markets fared better with the DAX gaining 0.1% to close at 12,230 points and the Paris CAC 40 again putting on a strong performance, rallying 0.6% to close at 5121 points.

On the commodities front, oil rallied strongly, resulting in some energy stocks providing index support.

Gold gained a little ground to close at US$1253 per ounce.

Base metals drifted lower across the board with nickel retracing 1.7% after a strong rally in the previous session.

The other main mover was zinc as it came off 1.6% to finish at US$1.22 per pound, pushing closer to the one month low of US$1.21 per pound.

The Australian dollar is fetching US$0.754.

This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X